CNSY:NASDAQ
Cerenome, Inc.
$1.71
arrow_upward
+0.88%(+0.015) 1D
Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$1.74
High
$1.83
Low
$1.70
Mkt. cap
12.98M
Avg. vol.
143.10K
Volume
0.00
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
Open
$1.74
High
$1.83
Low
$1.70
Mkt. cap
12.98M
Avg. vol.
143.10K
Volume
0.00
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
FinancialContent
·
1 hour ago
Yum China (NYSE:YUMC) misses Q3 2026 sales expectations
The Chronicle-Journal
·
15 minutes ago
Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations
The Motley Fool
·
25 minutes ago
The S&P 500's Record Profits Are Hiding a Problem Investors Haven't Seen Before
Barchart.com
·
15 minutes ago
Nasdaq Futures Climb as Chip Stocks Rebound; U.S. Midterms in Focus
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.